The main goals of therapy for patients with heart failure with preserved ejection fraction are to address the signs and symptoms of heart failure, improve quality of life, and reduce the risk of ...

Patients with heart failure with preserved ejection fraction (HFpEF) present with non-specific symptoms ... The intervention will focus on improving diagnostic process, decreasing physician burden and ...

The message is that an early decrease in eGFR with finerenone should not lead to stopping the medication, say HF experts.

The new approach is designed to create a connection between the left and right atrial chambers of the heart in a single ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

Japan: New research suggests that elevated plasma progranulin levels in the acute phase of acute myocardial infarction (AMI) ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.

Alleviant Medical announced that it received FDA investigational device exemption and breakthrough device designation for its ...

which minimized the confounder that patients with systolic heart failure whose ejection fraction might have improved with concurrent treatments were enrolled into this study. I-PRESERVE ...